Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 10,000 Shares of Stock

August 13, 2026 by InsiderTrades.com

Key Points

CEO Claire Mazumdar sold 10,000 shares at an average price of $27.98, generating $279,800. The transaction was made under a pre-arranged Rule 10b5-1 plan, and she retained 362,152 shares.
Bicara reported a quarterly loss of $0.82 per share, in line with analyst expectations, while management said enrollment in its pivotal cancer study remains on track for 2026.
Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $32.73, though targets range from $23 to $42 and at least one analyst maintains a sell rating.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $279,800.00. Following the completion of the sale, the chief executive officer owned 362,152 shares of the company's stock, valued at $10,133,012.96. This represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

On Friday, July 10th, Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00.

Bicara Therapeutics Stock Up 3.7%

Shares of Bicara Therapeutics stock opened at $24.63 on Thursday. Bicara Therapeutics Inc. has a twelve month low of $10.30 and a twelve month high of $30.99. The company's 50 day moving average is $26.00 and its 200 day moving average is $21.74. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -7.95 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts' consensus estimates of ($0.82). Sell-side analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current fiscal year.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

Positive Sentiment: Bicara reported second-quarter loss of $0.82 per share, matching consensus expectations. More importantly, management said enrollment in its pivotal cancer study remains on track for 2026, providing a potentially important clinical catalyst. Bicara Therapeutics stock gains as pivotal trial enrollment advances
Positive Sentiment: Analyst sentiment improved following the quarterly update. BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, while other analysts also lifted forecasts. The broader consensus remains a Moderate Buy with an average target of approximately $32.73. Analysts raise Bicara Therapeutics forecasts
Positive Sentiment: Wedbush reiterated that Bicara’s cancer study is on track for 2026 enrollment, supporting the view that the company could deliver meaningful development milestones in the near term. Bicara Therapeutics cancer study remains on track
Neutral Sentiment: Analyst views remain mixed. Wells Fargo raised its target from $16 to $23 but kept an Equal Weight rating, while other firms maintain more bullish targets. Bicara also announced strategic leadership transitions as it enters its next execution phase. Wells Fargo price-target update
Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for about $1.15 million. The transactions were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial stakes, which reduces—but does not eliminate—the negative signal from the insider selling. Bicara insider transaction filings

Analysts Set New Price Targets

Several brokerages recently commented on BCAX. Morgan Stanley lifted their price objective on Bicara Therapeutics from $37.00 to $39.00 and gave the stock an "overweight" rating in a report on Tuesday. Cantor Fitzgerald reissued an "overweight" rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Guggenheim started coverage on Bicara Therapeutics in a research report on Monday, May 11th. They issued a "buy" rating and a $42.00 target price on the stock. Wells Fargo & Company boosted their price target on Bicara Therapeutics from $16.00 to $23.00 and gave the company an "equal weight" rating in a research note on Wednesday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $32.73.

Get Our Latest Stock Analysis on BCAX

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in Bicara Therapeutics during the 1st quarter worth approximately $248,000. Woodline Partners LP lifted its holdings in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company's stock valued at $4,543,000 after purchasing an additional 72,998 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company's stock worth $6,248,000 after purchasing an additional 180,833 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Bicara Therapeutics by 26.0% in the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company's stock worth $255,000 after purchasing an additional 5,664 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter.

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.